X

DLBCL

DLBCL

Ibrutinib Plus R-CHOP for Younger Patients With DLBCL

New evidence suggests that adding the BTK inhibitor ibrutinib to a standard chemotherapy regimen may improve survival among younger people with a specific form of DLBCL.

The ASCO Post
11/05/2021
Which New Therapeutics Are Generating Excitement at This Year’s ICML?

Dr Salles summarizes preclinical data on a histone deacetylase inhibitor investigated for T-cell lymphoma, as well as data on bispecific antibodies investigated for DLBCL.

06/28/2021
IELSG30: Treating Primary Testicular DLBCL

Dr Annarita Conconi summarizes the results of the Phase II IELSG30 trial assessing R-CHOP, intravenous methotrexate, liposomal cytarabine, and scrotal irradiation in patients with primary DLBCL of the testis.

06/30/2021

Sequencing Treatment Options in Primary Refractory DLBCL

 

Davies begins by outlining a specific patient case, caveats in the current treatment options for DLBCL, and the patterns of primary refractory DLBCL.

06/25/2021
First-in-Human Trial of ALLO-501A in R/R Large B-cell Lymphoma

Dr Michael Tees discusses the first-in-human data of ALLO-501A, an allogeneic CAR-T product under investigation in relapsed/refractory large B-cell lymphoma in the ALPHA2 study.

06/21/2021
R-CHOP Dose Intensity and Survival Outcomes in DLBCL

Chan Yoon Cheah, MBBS, discusses the results of a systematic review investigating the impact of R-CHOP dose intensity on survival outcomes in patients with DLBCL.

06/02/2021
Outcomes of CAR-T Therapy in Patients With Refractory B-Cell Lymphoma

Dr Bruce Levine reports on the outcomes for refractory B-cell Lymphoma patients with CAR T-cell therapy.

04/23/2021
Is Mosunetuzumab Safe and Effective for Elderly Patients With Untreated DLBCL?

Dr Olszewski reports the results of a phase I/II clinical trial of mosunetuzumab as a first-line treatment for elderly and unfit patients with diffuse large B-cell lymphoma.

12/17/2020
Ibrutinib Therapy Prior to Tisa-Cel in R/R DLBCL

Dr Frederick Locke discusses the results of a Phase Ib safety trial of tisagenlecleucel in combination with ibrutinib, a BTK inhibitor, in R/R diffuse large B-cell lymphoma patients.

12/16/2020
Changes in the Classification of DLBCL

Dr Andrew Davies discusses heterogeneity within diffuse large B-cell lymphoma and how molecular profiling of tumor clones can allow reclassification of the disease.

06/22/2020
Alexander Study: CD19/22 Dual Targeting CAR T-Cell Therapy With Pembrolizumab in R/R DLBCL

During the ASCO Annual Meeting, the Lymphoma Hub speaks to Dr Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

06/02/2020
CAR-T Moving Forwards for R/R DLBCL

Dr Anna Sureda gives an overview of first line therapies and the role of stem cell transplantation and CAR-T therapy in the treatment of DLBCL.

03/22/2021
New Models for NHL Care: Innovative Therapy in FL and DLBCL

Dr Nathan H. Fowler, Dr Martin Dreyling, Dr Caron Jacobson and Dr Krish Patel discuss non-Hodgkin lymphoma in this CME activity titled Building New Management Models for NHL Care...

03/04/2021
New Options When DLBCL Doesn’t Respond to Treatment

Linda Bohannon interviews Dr Kami Maddocks about the newest treatments for relapsed/refractory DLBCL.

02/23/2021
Mosunetuzumab for Chemotherapy-Intolerant DLBCL

Dr Adam Olszewski shares the preliminary results of the ongoing Phase I/II trial assessing the safety and efficacy of mosunetuzumab in patients with DLBCL who are intolerant to chemotherapy.

12/14/2020
ZUMA-9: Expanded Access Protocol and OOS Axicabtagene Ciloleucel in R/R DLBCL

Dr Frederick Locke outlines the results of the ZUMA-9 trial of out-of-specification or expanded access to axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B-cell lymphoma patients.

12/06/2020
Real-World Efficacy & Safety Data: CAR-T in DLBCL

Dr Matthew Frigault comments on the key clinical trials involved in CAR T-cell therapy for the treatment of refractory DLBCL including results from ZUMA-1, JULIET, and TRANSCEND studies.

08/30/2020
Current Treatment Landscape of DLBCL

Dr Edmund Waller explores the current treatment landscape of DLBCL and discusses future approaches being developed, including earlier infusion of CAR T-cell therapies as evaluated in various studies.

08/30/2020
Bi-Specific Antibody - DLBCL and Follicular Lymphoma

Dr Joshua Brody discusses updates from ASH, highlighting DLBCL treatment. 

05/11/2020
Looking Beyond R-CHOP in Diffuse B-Cell Lymphoma

Dr Farzanna Haffizulla interviews Dr Brad Kahl on looking beyond R-CHOP in diffuse b-cell lymphoma.

01/05/2021

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
#cc529a
#c59445
#c8cc0c
#bf6be3
rgb (245, 152, 2)
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834